We have previously described an approach that employs retroviral receptor-ligand bridge proteins to target retroviral vectors to specific cell types. To determine whether targeted retroviral entry can also be achieved using a retroviral receptor-single-chain antibody bridge protein, the TVA-MR1 fusion protein was generated. TVA-MR1 is comprised of the extracellular domain of the TVA receptor for subgroup A avian leukosis viruses (ALV-A), fused to the MR1 single-chain antibody that binds specifically to EGFRvIII, a tumor-specific form of the epidermal growth factor receptor. We show that TVA-MR1 binds specifically to a murine version of EGFRvIII and promotes ALV-A entry selectively into cells that express this cell surface marker. These studies demonstrate that it is possible to target retroviral vectors to specific cell types through the use of a retroviral receptor-single-chain antibody fusion protein.
Several different strategies have been developed for targeting infection of specific cell types by retroviral vectors. The most common approach has employed recombinant viral envelope (Env) proteins that contain either cell type-specific ligands or single-chain antibodies that bind to specific cell surface molecules (1, 4, 7-12, 15, 18-20, 24-28, 31-35, 38, 39, 41, 42, 44, 46, 48, 51-54, 57) . This approach requires that the specific alterations made to Env do not affect the biosynthesis, virion assembly, or fusogenic function of the viral glycoprotein (12, 54, 57) .
An alternative approach for targeting retroviral entry that employs soluble retroviral receptor-ligand bridge proteins was recently developed (5, 47) . These bridge proteins are bifunctional reagents: the ligand moiety binds to specific cell surface receptors and the retroviral receptor moiety binds to Env, activating viral entry. This technique does not require making alterations to the viral glycoprotein but instead relies on "wildtype" Env-receptor interactions to target viral entry.
To demonstrate the feasibility of this approach, the TVA-EGF and TVB-EGF fusion proteins were generated. These bridge proteins contained human epidermal growth factor (EGF) fused to the extracellular domains of either the TVA receptor for subgroup A avian leukosis viruses (ALV-A) or the TVB receptor for ALV-B and ALV-D, respectively. Each of these bridge proteins promoted specific retroviral entry into cells that express the EGF receptor (EGFR) when bound to cell surfaces before viral challenge (5, 47) . Furthermore, murine leukemia virus (MLV) pseudotypes bearing ALV-B Env (EnvB) and preloaded with TVB-EGF were targeted specifically to cells that express EGFR (5) . These data demonstrated that retroviral vectors could be targeted to specific cell types by binding retroviral receptor-ligand bridge proteins to virions or to cell surfaces before viral challenge.
To extend the utility of this approach, we have now asked whether targeted retroviral entry into cells can also be achieved using TVA-MR1, a bridge protein that contains the extracellular domain of TVA fused to the MR1 single-chain antibody. This antibody binds specifically to the extracellular region of EGFRvIII, a variant form of the EGFR that is expressed at the surface of human tumor cells, including those derived from lung and breast carcinomas and glioblastomas (14, 17, 30, 37, 40, 49, 55, 56) . EGFRvIII lacks a substantial portion of the extracellular domain of the wild-type receptor as a consequence of a deletion or rearrangement that commonly occurs when the EGFR gene is amplified during tumor biogenesis. These alterations result in constitutive, ligand-independent activation of EGFRvIII (22) , which, in turn, confers a transformed phenotype upon various cell lines (22, 40) .
The MR1 antibody binds to a novel polypeptide sequence that is formed at the site of the deletion or rearrangement that gives rise to EGFRvIII (29) . The combination of the tumorrestricted expression of EGFRvIII and the binding specificity of the MR1 antibody makes this an attractive model system to test whether retroviral receptor-single-chain antibody bridge proteins can mediate targeted viral entry into cells. In this report, we demonstrate that TVA-MR1 can support efficient and specific ALV entry into mammalian cells that have been engineered to express a murine form of EGFRvIII.
MATERIALS AND METHODS

Viruses and immunoadhesins.
The SUA-rIgG immunoadhesin was described elsewhere and is comprised of the surface protein of the Schmidt-Ruppin A strain of Rous sarcoma virus fused to a rabbit Fc chain (58) . ALV-A-specific vectors encoding the enhanced green fluorescent protein (EGFP; Clontech) were generated by transfection of DF1 cells (45) with the RCASBP(A)-EGFP plasmid (provided by Mark Federspiel and Matt van Brocklin). The transfected cells were propagated until 100% of the population expressed EGFP as determined by fluorescence microscopy. Cells were then seeded in 1,700-cm 2 roller bottles, and virions were harvested every 12 h in 50 ml of medium that was equilibrated with 5% CO 2 . This medium was pooled and filtered through 0.45-m-pore-size filters and stored at Ϫ80°C. Before use, the virus-containing supernatants were thawed and subjected to centrifugation at 109,000 ϫ g for 1.5 h at 4°C. The viral pellets were then resuspended overnight at 4°C in 1/100 of the original volume of TNE buffer (5 Stocks of MLV vectors pseudotyped with the VSV-G protein were prepared from human 293T cells by using a transient transfection system essentially as described previously (5) with 5 g of the pMD.G plasmid encoding VSV-G, 15 g of the pMD.old.gagpol plasmid encoding MLV Gag and Pol, and 15 g of either plasmid pSFG.EGFRvIII or plasmid pMMP.TVA syn . Virions were harvested at 48 and 72 h postinfection, and the supernatants containing MLVEGFRvIII(VSV-G) and MLV-TVA syn (VSV-G) viruses were separately pooled and filtered through a 0.45-m-pore-size filter and then stored at Ϫ80°C.
Cell lines. Human 293T cells were propagated in Dulbecco modified Eagle medium containing 5% fetal bovine serum. 293T-EGFRvIII cells were generated by transducing 293T cells with MLV-EGFRvIII(VSV-G). Approximately 72 h after viral challenge, the transduced cell population (10 7 cells) was incubated for 30 min at 4°C with 5 ml of extracellular supernatant containing TVA-MR1 and then with 5 ml of extracellular supernatant containing SUA-rIgG. These cells were then incubated for 10 min at 4°C with a fluorescein isothiocyanate (FITC)-conjugated swine anti-rabbit antibody (DAKO Corp.) diluted 1:100 in medium. The cells were washed with ice-cold medium, and those expressing the EGFRvIII protein were isolated by flow cytometric sorting using a Coulter Epics Elite cell sorter. 293T-TVA syn cells were generated in a similar manner, except that 293T cells were transduced with MLV-TVA syn (VSV-G). Cells expressing the TVA syn receptor were isolated by flow cytometric sorting after binding SUA-rIgG to the cells for 30 min at 4°C, followed by binding the FITC-conjugated anti-rabbit antibody; 25% of these cells with the highest level of cell surface TVA syn were then isolated by subjecting the population to an additional round of flow cytometric sorting.
Construction and expression of TVA-MR1. A DNA fragment encoding the MR1 single-chain antibody (29) was generated by PCR amplification, using as template DNA the plasmid pCMMP.MR1, which contains a gene encoding MR1 located between the XbaI and HindIII restriction enzyme sites of the pCMMP vector (T. Niederman et al., unpublished data), and the following two oligonucleotide primers: 5Ј-GAACTCCTAGGGGGACCGCAGGTACAACTCCAGC AGTCCGGGGG-3Ј and 5Ј-GAGGGGCCCTCTAGATTATAGAGCTTTTTC AAGCTTGGTGCCATCACCG-3Ј. The resultant DNA fragment was digested with ApaI, end repaired with the Klenow fragment of DNA polymerase, and digested with AvrII to generate a 758-bp DNA fragment encoding MR1. This fragment was then ligated with plasmid pSS8 that had been cut with Asp718, end repaired, and then digested with AvrII. Plasmid pSS8 contains the gene encoding a TVA-heregulin␤1 fusion protein (S. Snitkovsky and J. Young, unpublished data) located between the EcoRI and HpaI restriction enzyme sites of the pCI expression vector (Promega). The resultant plasmid pSS11 encodes the TVA-MR1 fusion protein, and the authenticity of this open reading frame was confirmed by DNA sequence analysis (performed by the core DNA sequencing facility in the Department of Microbiology and Molecular Genetics at Harvard Medical School).
To generate the TVA-MR1 fusion protein, plasmid pSS11 was transfected into human 293 cells as described previously (47) . Aliquots of 40 l of extracellular supernatant taken from transfected and nontransfected human 293 cells were subjected to electrophoresis on 10% polyacrylamide gel containing sodium dodecyl sulfate under nonreducing conditions. The proteins were then transferred to a nitrocellulose membrane, and TVA-MR1 was detected by immunoblotting with 10 ml of extracellular supernatant containing SUA-rIgG and then with a horseradish peroxidase-conjugated antibody specific for rabbit immunoglobulins (Amersham), followed by enhanced chemiluminescence.
TVA-MR1 binding studies. A suspension of 3.5 ϫ 10 5 293T-EGFRvIII cells was incubated for 1 h at 4°C with increasing amounts of TVA-MR1-containing extracellular supernatant. These samples were made up to a total volume of 500 l with 293 cell-conditioned medium (medium that was obtained from a confluent monolayer of human 293 cells). A suspension of 3.5 ϫ 10 5 293T cells was incubated for 1 h at 4°C with 500 l of extracellular supernatant that either lacked or contained TVA-MR1. Both cell populations were then washed with 2 ml of ice-cold phosphate-buffered saline (PBS) and incubated for 1 h at 4°C with 500 l of extracellular supernatant containing SUA-rIgG. The cells were washed again with ice-cold PBS and incubated for 30 min at 4°C with the FITC-conjugated swine anti-rabbit antibody (diluted 1:100) in medium. The cells were then washed again and resuspended in 500 l of ice-cold PBS containing 1% formaldehyde, and the bound TVA-MR1 fusion proteins were detected by flow cytometry using a Coulter Epics Ex-L instrument.
The peptide competition binding experiments were performed by incubating 500 l of extracellular supernatant containing TVA-MR1 for 1 h at 4°C with a final 100 nM concentration of either the MR1 epitope-containing peptide (LEEKKGNYVVTDH) (29) or a scrambled (control) version of this peptide (YKELGVEVDNKHT). These samples were then incubated with 293T-EGFRvIII cells for 1 h at 4°C. TVA-MR1 proteins that were bound to the cells were then detected using SUA-rIgG and the FITC-conjugated antibody as described above. For control purposes, 500 l of 293 cell supernatants containing a 100 nM concentration of either the MR1 epitope-containing peptide or of the control peptide was placed on ice for 1 h and then incubated with 293T-TVA syn cells for an additional hour. The cells were then washed with ice-cold PBS, and cell surface TVA syn proteins were detected by flow cytometry as described above.
TVA-MR1-mediated infection.
Following each of these incubations, the cells were washed and resuspended in 500 l of medium with or without 5 l of 100-fold-concentrated RCASBP(A) Peptide competition experiments were performed by incubating 500 l of extracellular supernatant containing TVA-MR1 at 4°C for 1 h with a 100 nM concentration of either the MR1 epitope-containing peptide or of the control peptide. These samples were then incubated with 293T-EGFRvIII cells for another hour at 4°C. The cells were then washed and incubated for 1 h with 500 l of medium containing 5 l of 100-fold-concentrated RCASBP(A)-EGFP before plating and incubation at 37°C for 18 h. The medium was then replaced, and 72 h after viral challenge, the cells were analyzed by flow cytometry as described above.
RESULTS
Production of the TVA-MR1 protein.
A gene that encodes the recombinant TVA-MR1 bridge protein was constructed in plasmid pSS11 (described in Materials and Methods). TVA-MR1 is comprised of the extracellular portion of the TVA receptor (2) fused to the N terminus of the MR1 single-chain antibody, which recognizes a unique sequence in the extracellular domain of EGFRvIII (29) (Fig. 1A) . A proline-rich polypeptide linker that was described previously (47) was inserted between each of the two domains of TVA-MR1 (Fig.  1A ) in order to maximize the probability that each domain would fold and function independently. TVA-MR1 was produced as a secreted protein, approximately 54 kDa in size, in the extracellular supernatants taken from human 293 cells transfected with plasmid pSS11 (Fig. 1B, compare lanes 1 and  2) .
TVA-MR1 specifically binds to cells expressing an EGFRvIII protein.
To determine whether the Env-binding and antigen-binding domains of TVA-MR1 can each function independently, we investigated whether this bridge protein can bind both to the ALV-A surface envelope (ALV-A SU) and to a cell surface EGFRvIII protein. Transfected human 293T cells expressing a murine form of EGFRvIII (293T-EGFRvIII cells)
were incubated with increasing amounts of an extracellular supernatant containing TVA-MR1. For control purposes, the parental 293T cells were also incubated with TVA-MR1-containing supernatant. The bridge proteins that were bound to these cells were then detected by flow cytometry after the cells had been incubated with SUA-rIgG, an immunoadhesin composed of the ALV-A surface envelope fused to a rabbit Fc chain (58) , and with an FITC-conjugated secondary antibody. TVA-MR1 bound specifically and in a dose-dependent manner to 293T-EGFRvIII cells ( Fig. 2A) , indicating that this bridge protein can bind simultaneously to both ALV-A SU and to cell surface EGFRvIII.
To obtain direct evidence that TVA-MR1 binds to the EGFRvIII protein, we examined whether the interaction of this bridge protein with 293T-EGFRvIII cells could be blocked by a synthetic peptide that contains the target epitope for the MR1 antibody (29) . Indeed, this peptide blocked the binding of TVA-MR1 to these cells (Fig. 2B) . By contrast, a control peptide (with the same amino acids scrambled in a different order) did not affect TVA-MR1 binding to these cells (Fig.  2B) . To rule out the possibility that the MR1 epitope-containing peptide interfered nonspecifically with ALV-A SU-TVA interactions, this peptide was also tested for its effect on the binding of SUA-rIgG to a stably transfected line of human 293T cells (designated as 293T-TVA syn ) that express a transmembrane form of the TVA receptor. The MR1 epitopecontaining peptide did not block the binding of SUA-rIgG to these cells (Fig. 2C) , confirming that this peptide specifically blocks the interaction between TVA-MR1 and the EGFRvIII protein. (Table 1) (Fig. 3, compare panels B and  C) . Indeed, TVA-MR1 acted in a dose-dependent manner to increase the susceptibility of these cells to ALV-A infection (data not shown). In these experiments, the level of TVA-MR1-mediated viral entry into 293T-EGFRvIII cells was 8.5% of the level seen with 293T-TVA syn cells, and titers of approximately 10 8 infectious units/ml of 100-fold-concentrated virus were achieved (Table 1 ). In contrast, the addition of this bridge protein had no effect upon the susceptibility of the parental 293T cells to viral infection (Table 1) (Fig. 3 , compare panels E and F).
TVA-MR1 mediates specific ALV-A entry into 293T-EGFR-
To confirm that TVA-MR1 had to be bound to the EGFRvIII protein in order to mediate enhanced levels of viral entry into 293T-EGFRvIII cells, we determined whether this effect could be blocked by the MR1 epitope-containing peptide. The MR1 epitope-containing peptide, but not the control peptide, blocked this bridge protein-dependent viral infection (Fig. 4) . Therefore, TVA-MR1 is capable of facilitating targeted ALV-A entry into mammalian cells when bound to the EGFRvIII protein.
DISCUSSION
In this report we have demonstrated the feasibility of using a soluble retroviral receptor-single-chain antibody bridge protein for targeting retroviral infection to a specific cell type. Cell-binding studies and peptide competition experiments confirmed that TVA-MR1 is a bifunctional reagent that can bind to a cell surface EGFRvIII protein expressed on 293T cells and to ALV-A SU. Furthermore, the binding of TVA-MR1 to the EGFRvIII protein allowed specific viral entry at a level that was approximately 7% (ranging from 1.8 to 14% in separate experiments) of that found in ALV-A infection of 293T-TVA syn cells (Table 1 and data not shown). In contrast, TVA-MR1 did not bind to or promote infection of the parental 293T cells, which are known to express cell surface EGFRs (50) . Indeed, based upon previous results that demonstrated the unique specificity of the MR1 antibody for EGFRvIII, we fully expected that TVA-MR1 would allow only ALV-A infection of cells expressing mutant, but not wild-type, EGFRs. For example, Lorimer et al. (29) have already shown that this singlechain antibody, engineered in the context of an MR1-toxin fusion protein, directs the potent killing of cells that express 400,000 EGFRvIII molecules (at a concentration of 7 to 10 ng/ml), whereas this recombinant toxin is unable to kill cells expressing 200,000 wild-type EGFR molecules even when added at concentrations as high as 1,000 ng/ml. Taken together, our studies have demonstrated that TVA-MR1 can be an efficient and specific facilitator of viral entry into cells when bound to EGFRvIII.
During these experiments we found that ALV-A is capable of infecting human 293T cells and 293T-EGFRvIII cells at a low "background" level that was 1/2,000 to 1/5,000 of the level seen with 293T-TVA syn cells (Table 1 and data not shown). The addition of TVA-MR1 led to an 180-fold to 200-fold increase in the susceptibility of 293T-EGFRvIII cells to ALV-A infection but did not affect the "background" level of infection seen with 293T cells (Table 1 ). The "background" level of ALV-A infection seen with human 293T cells is similar to that seen with some other human cell lines, e.g., U250 glioma cells, but it is approximately 100-fold higher than that seen with other mammalian cell lines (6) . It is important to The results presented in this report suggest that it might be possible both in vivo as well as in vitro, to use retroviral receptor-single-chain antibody bridge proteins as tools to deliver retroviral vectors to specific cell types that express cognate cell surface antigens. With regard to in vivo applications, it is not yet clear whether the background level of ALV-A infection that was observed in cultured human 293T cells will represent a significant hurdle for cell type-specific viral targeting: viral targeting studies, performed with transgenic lines of mice that express a transmembrane form of TVA in specific cell types, indicate that the "background" level of ALV-A infection seen with cells that lack this viral receptor is extremely low (16) . Furthermore, in considering the potential utility of this system for delivering viral vectors to tumor cells, the use of ALVbased or MLV-based vectors for gene delivery affords another level of specificity since these viruses only establish proviral DNA in dividing cell types (36, 43) . Indeed, several groups have already shown that it is possible to use this feature of MLV vectors to deliver genes specifically to tumor cells, even in the absence of a selective Env-targeting system (13, 23) . However, since the retroviral vectors used in these studies have a broad host range, there exists the potential for infecting other dividing cell types in addition to the target tumor cells. The use of retroviral receptor-ligand and retroviral receptor-singlechain antibody bridge proteins for viral delivery may lead to more specific viral targeting in vivo. Indeed, it will be interesting to determine the efficiency and specificity of in vivo viral targeting that can be achieved with TVA-MR1 in mouse models of human cancer that employ tumor cells expressing EGFRvIII (21) . An added advantage of using retroviral receptor-single-chain antibody fusion proteins is that such bridge proteins might be useful for targeting retroviral vector infection to cells expressing a number of different cell surface factors, including those with no known ligands.
